Healthy
Conditions
Keywords
M01.774.500, Volunteers
Brief summary
The main goal of this study is to investigate the impact of aging on the responsiveness of peripheral blood immune cells. To this aim, the investigators will take advantage of a recently described syringe-based assay system that can reproducibly assess induced, innate or adaptive immune responses. Briefly, a total of 50 healthy volunteers will participate to this study: 25 will be older than 18 and younger than 30, and 25 will be older than 55. A total of 14 ml of blood will be drawn including 5 X 1 ml in TruCulture™ tubes containing poly(I:C), R-848, LPS, CpG, or no stimulus, respectively. After 22 hours of incubation at 37°C, cellular supernatants will assessed for levels of 10 different chemokines using a MesoScaleDiscovery multiplexing platform.
Interventions
OTHERHealthy Volunteers
A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
Sponsors
Centre Hospitalier Universitaire de Nice
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* volunteers will be invited to settle an appointment with the Nice University Hospital (CHU de Nice) Research Clinical Center (CRC). * being between 18 and 30 year-old (group Y) or being older than 55 year-old (group O), * ability to understand and speak French, * being registered at the Social Security, * acceptance to be serologically tested for HIV and HVC, * considered healthy based on both past medical records and the clinical examination performed at the inclusion visit, * exhibiting a body mass index (body mass divided by the square of their height) comprised between 18.5 and 30.0 kg/m2.
Exclusion criteria
* having participated to a drug clinical trial since less than 3 months, * having traveled to a tropical or a sub-tropical country over the past 3 months, * being pregnant or a lactating mother (for women), * having performed intensive physical exercise over the past 12 hours, * following a specific diet for medical reasons, * over-drinking, i.e. more that 50 g of pure alcohol every day, * having taken an immuno-suppressive or immuno-modulatory drug over the past two weeks, or for at least 14 consecutive days over the past 6 months, * having been vaccinated over the past 3 months, * declaring not being on an empty stomach for less than 12 hours, * having received a blood transfusion or intravenous immunoglobulins over the past 3 months, * declaring being HIV- or HVC- positive, * having suffered from an infection since less than 3 weeks, * exhibiting a positive urine pregnancy test at the inclusion visit, * suffering from a severe/chronic/relapsing pathology, i.e. inflammatory bowel disease, psoriasis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, type I or type II diabetes, Parkinson's disease, and (p) having been diagnosed with a cancer and not being in a remitting period for less than 5 years.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CCL2 levels | at first day | Compare CCL2 levels in the supernatants of poly(I :C)-stimulated whole blood cells between volunteers aged from 18 to 30 years and volunteers older than 55 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Other CCL levels | at first day | Compare CXCL8 (IL-8) levels in the supernatants of poly(I :C)-stimulated whole blood cells between volunteers aged from 18 to 30 years and volunteers older than 55 |
Countries
France
Outcome results
None listed